They also observed that a decrease of dasatinib concentration leads to activation of SRC–FAK signaling and cautioned about the possibility that type I SRC kinase inhibitors can evoke growth signals in vivo when the drug concentration decreases, thus accelerating cancer growth. Here, PTK2 is linked to cancer.